858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule medications that operate on oncology therapeutic targets, such as proteins that govern RNA and the innate immune response. Its platform assesses the impact of RNA-modifying proteins on disease biology and generates a pipeline of small compounds affecting key targets such as cancer.